Zoetis Inc. Share-based Payment Arrangement, Accelerated Cost
Zoetis Inc. (ZTS) reported Share-based Payment Arrangement, Accelerated Cost of $1.00 million for the 3-month period ending 2019-09-30, per its 10-Q filed 2019-11-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2020-11-05
- Zoetis Inc. share-based payment arrangement, accelerated cost for the quarter ending 2019-09-30 was $1.00M.
- Zoetis Inc. share-based payment arrangement, accelerated cost for the quarter ending 2019-06-30 was $2.00M.
- Zoetis Inc. share-based payment arrangement, accelerated cost for the quarter ending 2016-12-31 was $0.00.
- Zoetis Inc. share-based payment arrangement, accelerated cost for the quarter ending 2016-10-02 was $0.00.
- Zoetis Inc. share-based payment arrangement, accelerated cost for fiscal 2018 was $0.00.
- Zoetis Inc. share-based payment arrangement, accelerated cost for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- Zoetis Inc. share-based payment arrangement, accelerated cost for fiscal 2016 was $1.00M, a 50.00% decline from fiscal 2015.
- Zoetis Inc. share-based payment arrangement, accelerated cost for fiscal 2015 was $2.00M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month | Share-based Payment Arrangement, Accelerated Cost 9 month as first filed | Share-based Payment Arrangement, Accelerated Cost 12 month |
|---|---|---|---|---|---|
| 2019-09-30 | $1.00M 10-Q · filed 2019-11-07 | $3.00M derived: sum of 2 quarters · filed 2019-11-07 | $1.00M 10-Q · filed 2020-11-05 | $5.00M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $2.00M 10-Q · filed 2019-08-06 | $4.00M 10-Q · filed 2019-08-06 | |||
| 2018-12-31 | $0.00 10-K · filed 2019-02-14 | ||||
| 2017-12-31 | $0.00 10-K · filed 2018-02-15 | ||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $0.00 derived: sum of 2 quarters · filed 2018-02-15 | $1.00M 10-K · filed 2018-02-15 | ||
| 2016-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $1.00M 10-Q · filed 2017-11-02 | |||
| 2016-07-03 | $1.00M 10-Q · filed 2017-08-08 | ||||
| 2015-12-31 | $2.00M 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |